Viatris (VTRS) Total Liabilities (2019 - 2026)
Viatris' (VTRS) quarterly Total Liabilities came in at $22.2 billion in Q1 2026, down 2.84% year-on-year from $22.8 billion in Q1 2025, and down 1.36% quarter-over-quarter from $22.5 billion in Q4 2025.
Viatris (VTRS) Total Liabilities (2019 - 2026) Analysis & Trends
Viatris' Total Liabilities history runs 8 years deep, the most recent figure standing at $22.2 billion for Q1 2026.
- On a quarterly basis, Total Liabilities fell 2.84% year-over-year to $22.2 billion in Q1 2026; TTM through Mar 2026 was $22.2 billion, a 2.84% decrease from a year earlier, with the FY2025 full-year figure at $22.5 billion, down 1.68% from the prior year.
- Total Liabilities fell to $22.2 billion in Q1 2026 per VTRS's latest filing, from $22.5 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $33.0 billion in Q1 2022 and bottomed at $22.2 billion in Q1 2026.
- The 5-year median for Total Liabilities is $27.2 billion (2023), against an average of $26.4 billion.
- Biggest YoY gain for Total Liabilities was 1.68% in 2025; the steepest drop was 16.48% in 2025.
- Year by year, Total Liabilities stood at $28.9 billion in 2022, then slipped by 5.98% to $27.2 billion in 2023, then dropped by 15.99% to $22.9 billion in 2024, then decreased by 1.68% to $22.5 billion in 2025, then dropped by 1.36% to $22.2 billion in 2026.
- Per Business Quant, the three latest VTRS Total Liabilities figures stand at $22.2 billion (Q1 2026), $22.5 billion (Q4 2025), and $22.7 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.48 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 31.81 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.92 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 51.53 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 813.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 22.18 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.50 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.72 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 634.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.18 Bn |
| Dec 31, 2025 | 22.48 Bn |
| Sep 30, 2025 | 22.70 Bn |
| Jun 30, 2025 | 22.84 Bn |
| Mar 31, 2025 | 22.82 Bn |
| Dec 31, 2024 | 22.87 Bn |
| Sep 30, 2024 | 24.96 Bn |
| Jun 30, 2024 | 25.81 Bn |
| Mar 31, 2024 | 27.33 Bn |
| Dec 31, 2023 | 27.22 Bn |
| Sep 30, 2023 | 27.88 Bn |
| Jun 30, 2023 | 27.85 Bn |
| Mar 31, 2023 | 28.36 Bn |
| Dec 31, 2022 | 28.95 Bn |
| Sep 30, 2022 | 29.48 Bn |
| Jun 30, 2022 | 31.32 Bn |
| Mar 31, 2022 | 33.02 Bn |
| Dec 31, 2021 | 34.35 Bn |
| Sep 30, 2021 | 34.93 Bn |
| Jun 30, 2021 | 36.78 Bn |